Render Target: SSR
Render Timestamp: 2024-11-22T17:56:43.835Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:19:04.462
Product last modified at: 2024-05-30T07:01:31.346Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Interleukin-4 (hIL-4) #8919

We recommend the following alternatives

Inquiry Info. # 8919

Please see our recommended alternatives.

    Product Information

    Product Usage Information

    Reconstitution:

    With carrier: Add sterile PBS, or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final hIL-4 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

    Carrier free: Add sterile PBS, or PBS containing protein to minimize absorption of hIL-4 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hIL-4 should be greater than 50 μg/ml.

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-4. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 20
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-4. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hIL-4.
    Activity The bioactivity of recombinant hIL-4 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 80-250 pg/ml.
    Molecular Formula Recombinant hIL-4 does not have a Met on the amino terminus and the nonglycosylated protein has a calculated MW of 14,963. DTT-reduced and non-reduced protein migrate as larger 20 kDa polypeptides due to glycosylation, with non-reduced having slightly greater mobility due to an intramolecular cystine. The expected amino-terminal HKCDI of recombinant hIL-4 was verified by amino acid sequencing.

    Source / Purification

    Recombinant human IL-4 (hIL-4) His25-Ser153 (Accession #AF395008) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    IL-4 is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the TH2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching and expression of other TH2 cytokines including IL-5 and IL-9. IL-4 induced TH2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. Type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (3,4). Type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3 and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.